سعر ريباجلينيد 0.5مجم 30 اقراص 2026

Repaglinide 0.5 mg 30 tabs: repaglinide 0.5 mg oral tablets (30 tablets), a meglitinide (glinide) insulin secretagogue, listed in Egypt under Eipico.

• Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (not for type 1 diabetes or diabetic ketoacidosis).Population: Adults with type 2 diabetes mellitusDailyMed (U.S. National Library of Medicine)

• Hypoglycemia is the most common adverse reaction; others include upper respiratory infection, headache, sinusitis, arthralgia, nausea, diarrhea and back pain.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Concomitant use of gemfibrozil.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Known hypersensitivity to repaglinide or any inactive ingredient.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypoglycemia, which can be severe; risk increased by skipped meals, exercise, renal/hepatic impairment and interacting drugs; beta-blockers may mask symptoms.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Not indicated in combination with NPH insulin (myocardial ischemia events in trials).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No conclusive evidence of macrovascular risk reduction.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• GemfibrozilContraindicated: markedly increases repaglinide exposure.DailyMed (U.S. National Library of Medicine)
• ClopidogrelAvoid; if unavoidable start 0.5 mg before each meal and do not exceed 4 mg/day.DailyMed (U.S. National Library of Medicine)
• CyclosporineDo not exceed 6 mg repaglinide per day.DailyMed (U.S. National Library of Medicine)

• Limited human data have not identified a drug-associated risk of major birth defects, miscarriage or adverse outcomes; poorly controlled diabetes in pregnancy carries maternal and fetal risks.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No human milk data; because of potential hypoglycemia in breastfed infants, use while breastfeeding is not recommended.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Repaglinide: Short-acting stimulation of insulin release from pancreatic beta cells.